Time's Almost Up: Get Biotech Profile (NPHC) On Your Radar This AM, 5 Key Potential Catalysts
Did you know researchers estimate that 50 million adults in the United States are dealing with chronic pain. (1)
Dr. Robert Jason Yong, the medical director of the pain management center at Brigham, shared with Healthline(dot)com:
"Millions of Americans right now are suffering from chronic pain."
"It is the No. 1 reason why patients see a doctor."
"The impact of chronic pain on people’s lives is enormous."
You Think Sex Sells? Think Bigger...
When people are in pain, what do they typically turn to? Medicine.
The global pain management drugs market was valued at $71Bn in 2019, and is projected to reach $91Bn by 2027, registering a CAGR of 3.8% from 2020 to 2027. (4)
In the U.S., it appears we make up almost half of those figures.
The U.S. pain management drugs market was valued at $31Bn in 2019, and is projected to reach $39Bn by 2027, registering a CAGR of 3.4%. (2)
Those stats are frightening, and as research suggests, will only continue to grow in the years ahead.
That's why I have one profile above any others to get at the top of your watch-list Monday AM:
Nutra Pharma Corporation (NPHC)
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. Additionally, the Company markets drug products for sale for the treatment of pain under the brand Nyloxin® and Pet Pain-Away™.
Aren't We In The Middle Of An Opioid Crisis?
In the late 1990s, pharmaceutical companies reassured the medical community that patients would not become addicted to prescription opioid pain relievers, and healthcare providers began to prescribe them at greater rates.
This subsequently led to widespread diversion and misuse of these medications before it became clear that these medications could indeed be highly addictive.
Drugabuse(dot)gov shares (3):
- Roughly 21 to 29 percent of patients prescribed opioids for chronic pain misuse them.
- Between 8 and 12 percent of people using an opioid for chronic pain develop an opioid use disorder.
- An estimated 4 to 6 percent who misuse prescription opioids transition to heroin.
- About 80 percent of people who use heroin first misused prescription opioids.
So How Does Nutra Pharma Corporation (NPHC) Aim To Combat Chronic Pain?
Currently, Nutra Pharma Corporation offers several proprietary drug products for sale for the treatment of pain: Nyloxin® - the first over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain, Nyloxin® Extra Strength - the only non-prescription pain reliever for severe (Stage 3) pain and Pet Pain-Away™ - the first OTC product to treat pain in companion animals without side effects.
Nyloxin provides all-natural anti-inflammatory analgesic pain relief that is non-toxic, non-narcotic, non-addictive, non-steroidal and contains no aspirin or acetaminophen.
Nyloxin Is 100% Safe To Treat Chronic Arthritis And Joint Pain
Nyloxin is believed to work by targeting some of the same receptors on nerve cells that are also recognized by nicotine. These receptors are found in nerves outside the central nervous system (brain and spinal cord) and they are also found on cells of the immune system. Specialized proteins in Nyloxin block the action of acetylcholine, a major stimulating neurotransmitter in the nervous system and activator of the inflammatory pathways. As a result, the pain and inflammation pathways are temporarily shut off. In some clinical studies, Nyloxin pain relieving products could provide prolonged chronic muscle and joint relief.
NPHC Is Also Working On Treatments For Viral And Neurological Diseases In Humans
Nutra Pharma is developing proprietary therapeutic protein products primarily for the prevention and treatment of viral and neurological diseases in humans. The emphasis of Nutra Pharma's approach to drug discovery and the development of new therapeutic agents is based upon specialized receptor-binding proteins found in nature, especially those found in snake venom from cobras.
Leading Drug Candidates
RPI-MN inhibits the entry of several viruses that are known to cause severe neurological damage in such diseases as encephalitis and AIDS. It is being developed first for the treatment of HIV. and Herpes.
RPI-78M is being developed for the treatment of multiple sclerosis (MS). Other neurological and autoimmune disorders that may be served by RPI-78M include myasthenia gravis (MG), rheumatoid arthritis (RA) and amyotrophic lateral sclerosis (ALS).
*RPI-78M has received Orphan Drug Designation from the FDA for the treatment of Pediatric Multiple Sclerosis
RPI-78M and RPI-MN contain anticholinergic peptides that recognize the same receptors as nicotine (acetylcholine receptors) but have the opposite effect. In a specific chemical process unique to Nutra Pharma, the drugs are created through a process of chemical modification and possess several desirable properties as drugs, including:
- They lack measurable toxicity but are still capable of attaching to and affecting the target site on the nerve cells. This means that patients cannot overdose.
- They display no serious adverse side effects following years of investigations in humans and animals.
- They are extremely stable and resistant to heat, which gives the drugs a long shelf life. The drugs' stability has been determined to be over 4 years at room temperature. This is extremely unusual for a biologic drug.
- They are easy to administer.
- RPI-78M can be administered orally-a first for a biologic MS drug. This will present MS patients with additional quality of life benefits by eliminating the requirement for routine injections.
Nutra Pharma is taking on some of the world's most difficult diseases including:
RPI-MN: Modified Cobra Venom for Viral Diseases
Herpes is a group of related diseases marked by the development of blisterlike sores on the skin or mucous membranes of the body.
Human Immunodeficiency Virus (HIV / AIDS)
The Human Immunodeficiency Virus (HIV) is the virus that causes AIDS, a debilitating and deadly disease of the human immune system. The World Health Organization (WHO) estimates that 35 million people have died from AIDS since 1981. It is estimated that at the end of 2016, there were more than 36 million people worldwide living with HIV.
RPI-78M: Modified Alpha Cobratoxin for Autoimmune Diseases
Adrenomyeloneuropathy (AMN) is a rare inherited metabolic disorder that affects approximately 20,000 people globally. Its symptoms are very similar to those of progressive Multiple Sclerosis (MS).
Multiple Sclerosis (MS)
Multiple Sclerosis (MS) is a chronic autoimmune disease of the central nervous system causing muscular weakness, loss of coordination, and speech and visual disturbances. There are approximately 2,000,000 people living with MS worldwide.
And, right now, NPHC has several potential catalysts that could provide it with fuel towards a possible vertical move. Here's what you need to know:
Your No. 1 Potential NPHC Catalyst
Nutra Pharma Files Updated Provisional Patent for Nerve Agent Countermeasures
Nutra Pharma has filed an updated provisional patent for the protection of their intellectual property surrounding the use of RPI-78M and analogs of the drug as potential counter-measures against organophosphate nerve agents
Plantation, Florida , July 23, 2021 (GLOBE NEWSWIRE) -- Nutra Pharma Corporation (OTC Pink: NPHC), a biotechnology company marketing Nyloxin®, Pet Pain-Away™, Luxury Feet™ and Equine Pain-Away™ in the over-the-counter (OTC) pain management market and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV) and Pain, announced today that they have filed a new provisional patent to protect their intellectual property surrounding their development of nerve agent countermeasures.
"We originally announced this project in early 2018,” stated Rik J Deitsch, Chief Executive Officer of Nutra Pharma. “In much the same way that our therapies protect the nerves of patients with disease, our findings indicate that we may protect against – or at least mitigate the damage caused by - nerve agents that are utilized as chemical weapons; such as sarin gas and VX,” he continued. “As we have pursued this project and gathered additional data, we are now filing new and updated intellectual property surrounding these findings and will be working with experts in the field to have our products in testing shortly. To that end, we will be working with governmental agencies, Universities and private collaborators as we seek to further this research and potentially license the technology,” he concluded.
RPI-78M was originally derived from an extract of cobra venom and is an antagonist of the nicotinic acetylcholine receptor. The drug has a remarkably low toxicity with a very large therapeutic window. Scientific publications have demonstrated that native and modified neurotoxins can protect nerve cells from early cell death. Furthermore, it is expected that RPI-78M may be beneficial in neuromuscular disorders where the activity of nicotinic acetylcholine receptor has been compromised. The proprietary technology is covered by patents describing the application and use of RPI-78M in the treatment of autoimmune diseases, including Multiple Sclerosis (MS).
“The company has very encouraging in vivo and in vitro preclinical data, a demonstrated molecular mechanism of action and a robust scientific rationale for the continued commercial development of its nerve agent countermeasure,” reported Dale VanderPutten, PhD, Chief Scientific Officer of Nutra Pharma. “The use of organophosphate nerve weapons (Soman, VX, Novichok, etc) is unfortunately increasing,” he continued. “The successful use of these weapons by states and terrorist groups regretfully emboldens others to use them as well. These weapons are also becoming increasingly sophisticated without any advancements in new protective agents. We believe that our nAChR-directed countermeasure may provide an important tool for military and civilian defenses against these horrifying weapons,” Dr. VanderPutten concluded.
Read the full article here.
Your No. 2 Potential NPHC Catalyst
As of 11:00AM EST on Friday, Barchart was reporting this profile to have at least 9 triggered technical indicators across the short, medium, and long terms.
Here's a complete list:
Short Term Indicators
- 20 Day Moving Average
- 20 - 50 Day MACD Oscillator
- 20 - 200 Day MACD Oscillator
Medium Term Indicators
- 50 Day Moving Average
- 50 - 200 Day MACD Oscillator
Long Term Indicators
- 100 Day Moving Average
- 150 Day Moving Average
- 200 Day Moving Average
- 100 - 200 Day MACD Oscillator
On top of that, NPHC was also trading above its 5-Day Exponential Moving Average (EMA) and its 13-Day Exponential Moving Average.
Furthermore, its 5-Day EMA was trading above its 13-Day EMA which signals a profile that is trending in a bullish manner recently.
Your No. 3 Potential NPHC Catalyst
Nutra Pharma Engages Government Affairs Consulting Firm
Nutra Pharma is working with Washington DC-based government affairs consultants and lobbyists to support their Nyloxin® line of pain relief products as well as act as liaisons to governmental agencies
Plantation, Florida, July 15, 2021 (GLOBE NEWSWIRE) -- Nutra Pharma Corporation (OTC Pink: NPHC), [...], announced today that they had engaged the Washington DC-based government affairs consulting firm, Vitello Consulting. The firm will work with elected officials as well as governmental agencies to increase the awareness of Nutra Pharma’s products and technologies with the goal of improving sales, garnering grants and potentially speeding drug applications.
“We are excited to work with Vitello Consulting as our liaisons with governmental agencies and elected officials,” explained Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. “We have high hopes that this relationship will allow us to get our products into the hands of the people that need them most. This includes our Veterans in chronic pain,” he continued. “One of the first projects for this new relationship will be working with the Veterans Administration to pave the way into VA hospitals and clinics. They will also help us navigate government bureaucracies that include the FDA, the SEC and buyers on the Federal Supply Schedule,” he concluded.
Nutra Pharma has several projects in front of governmental agencies at this time. The Company has previously announced their work with the Defense Threat Reduction Agency (DTRA) on their potential nerve agent counter-measures. Nutra Pharma had also been granted Orphan Designation by the FDA for their Multiple Sclerosis drug, RPI-78M and has stated plans to move the drug into clinical trials.
“We’re thrilled to be working with Nutra Pharma,” commented Frank Vitello, president of Vitello Consulting. “The pipeline Rik and his team have developed has them positioned for immediate success, and I’m confident that together we’ll cross the goal line on a number of these projects in the coming months,” he concluded.
Read the full article here.
Your No. 4 Potential NPHC Catalyst
Nutra Pharma Announces that Diverse Health Services has Added Nyloxin to Their Product Offerings
Diverse Health Services, an industry leader in Chiropractic care and Alternative Medicine, announced the addition of the Nyloxin(R) line of pain relief products to their marketplace
Plantation, Florida--(Newsfile Corp. - June 8, 2021) - Nutra Pharma Corporation (OTC Pink: NPHC), [...], announced that Diverse Health Services of Metro-Detroit has added the Nyloxin line of products to their offerings. Nyloxin is already being sold in-house at their facilities and will be added shortly to their online marketplace. Their marketing plan includes direct sales to patients and other medical facilities, sales through their websites and social media utilizing their online platforms as well as videos featuring Dr. R.E. Tent.
"We are pleased to be working with Diverse Health Services and Dr. Tent to expand the marketing of Nyloxin," explained Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. "Nyloxin is already being sold in physician offices, clinics and small-chain pharmacies: and we've been working diligently to introduce Nyloxin into the Chiropractic and Complementary medicine marketplace," he continued. "As a recognized voice in that community, Dr. Tent is the perfect distribution partner to open those doors and greatly expand the awareness of our products," he concluded.
Read the full article here.
Your No. 5 Potential NPHC Catalyst
Nutra Pharma Announces Private Label Expansion of their Over-The-Counter Pain Relievers
Nutra Pharma is announcing the first private label agreement in expansion of their line of over-the-counter pain relievers and anti-inflammatory drugs
Plantation, Florida--(Newsfile Corp. - June 4, 2021) - Nutra Pharma Corporation (OTC Pink: NPHC), [...], announced today their plans for increasing sales of their over-the-counter pain relievers through private label agreements that will rebrand Nyloxin. The first private label distributor contract has been executed with sales expected to start within the next 4-6 weeks. Their marketing plan includes direct sales, targeted landing pages and aggressive marketing through social media.
"We have been working diligently to brand our amazing products over the last few years and we have seen some consistent growth in online sales as well as into physician offices and small-chain pharmacies," commented Nina Goldstein, Marketing Manager of Nutra Pharma. "We will continue these efforts, but will be adding another sales layer by allowing expanded branding of our product technology through private labels with professional marketers and distributors," she continued. "This will allow increased sales to Nutra Pharma by expanding our customer base into markets not currently available to us. We have had small distribution through private labels in the past, but these new efforts will utilize developed sales channels that should see rapid growth and increase the overall awareness of our core technology; the use of cobra venom in the treatment of chronic pain and inflammation," she concluded.
Read the full article here.
Coverage if officially initiated on NPHC. When you have a second, do this: